Corporate
AAALAC International accreditation is a globally recognized benchmark for excellence in animal care and use programs. Achieving across all ERBC sites confirms full alignment with international animal welfare standards and best practices in preclinical and non-clinical research.
This Group-wide accreditation demonstrates ERBC’s commitment to:
For sponsors seeking a trusted European preclinical CRO, AAALAC accreditation provides assurance of robust infrastructure, controlled processes, and internationally recognized standards.
The accreditation of the Baugy site follows the construction of a new state-of-the-art building designed to deliver high-quality end-to-end preclinical programs.
This new facility expands ERBC’s scientific capabilities and offers highly flexible acclimatation programs, ensuring optimal study conditions while maintaining strict alignment with harmonized Group quality standards.
The Baugy expansion strengthens ERBC’s ability to conduct integrated development programs under GLP and non-GLP conditions, supporting early research, regulatory toxicology, safety assessment, and translational studies within a unified quality framework.
As the European preclinical end-to-end CRO, ERBC provides a comprehensive portfolio of integrated services covering the full spectrum of non-clinical development.
Comprehensive toxicology programs conducted under GLP and non-GLP conditions, supporting IND-enabling studies and regulatory submissions across international markets.
Core battery studies, in vitro and in vivo safety assessments, and follow-up investigations designed to evaluate potential adverse effects on vital organ systems.
Integrated laboratory capabilities including bioanalysis, analytical chemistry, histopathology, clinical pathology, PK/PD metabolism studies, and central laboratory services.
Comprehensive non-human primate supply and management solutions supporting complex preclinical research programs under strict ethical and quality standards.
Together, these integrated services enable seamless project management, scientific consistency, and reliable data generation aligned with global regulatory expectations.
Explore our full service portfolio here: https://www.erbc-group.com/services/
Early-stage research services designed to accelerate candidate selection and preclinical proof-of-concept, including in vivo models, efficacy studies, early derisking strategies, ADME/PK/PD, biodistribution, imaging, and specialized BSL2/BSL3 capabilities.
The global preclinical landscape continues to evolve, with growing regulatory scrutiny and increasing expectations from pharmaceutical and biotechnology sponsors.
By completing its AAALAC accreditation roadmap, ERBC reinforces its ability to provide:
As regulatory frameworks become more demanding, ERBC remains committed to delivering consistent, high-quality non-clinical research services supported by harmonized quality systems and deep scientific expertise.
AAALAC accreditation represents more than compliance. It reflects ERBC’s long-standing commitment to animal welfare, scientific rigor and responsible research practices.
Through sustained investment in infrastructure, quality harmonization, and integrated service capabilities, ERBC continues to strengthen its position as a leading European preclinical CRO delivering end-to-end solutions to global partners.
